Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CI 1033 · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| CI 1033 | DRUG | - |
| PACLITAXEL | DRUG | - |
| CARBOPLATIN | DRUG | - |
Inclusion Criteria: * Histologically or cytologically documented diagnosis of progressive or recurrent, locally advanced or metastatic NSCLC; a tumor that expresses at least one member of the erbB family of receptors; failed or relapsed after receiving a platinum-containing regimen as therapy; at l...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | ACE-536 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor, Ruxolitinib |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Incyte Corporation | INCY | 10 | PHASE2 | Ruxolitinib |
| GSK plc Sponsored ADR | GSK | 2 | PHASE2 | MMB |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Elritercept, Ruxolitinib |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY3410738, Venetoclax, Azacitidine |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Galecto, Inc. | GLTO | 1 | PHASE2 | GB2064 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | bomedemstat |
CI 1033 is an investigational small molecule being studied for the treatment of lung neoplasms, breast neoplasms, and non-small cell lung carcinoma. It has been evaluated in clinical trials for advanced non-small cell lung cancer, metastatic breast cancer, and as a first-line chemotherapy combination in non-small cell lung cancer patients.
CI 1033 is being developed by Pfizer, Inc., which trades under the ticker symbol PFE. The drug is an investigational small molecule in the oncology therapeutic area, and it has been studied in clinical trials for various cancer indications.
CI 1033 is in Phase 1 clinical development. It has completed three clinical trials, including two Phase 2 studies and one Phase 1 study. The drug is investigational and has not been approved by regulatory authorities.
CI 1033 has been studied in three completed clinical trials: NCT00050830, a Phase 2 study in advanced non-small cell lung cancer; NCT00051051, a Phase 2 study in metastatic breast cancer; and NCT00174356, a Phase 1 study combining CI 1033 with paclitaxel and carboplatin in non-small cell lung cancer.
Yes, CI 1033 and CI-1033 refer to the same drug. The name appears in clinical trial records with and without a hyphen, but both refer to the investigational small molecule being developed by Pfizer for the treatment of lung and breast cancers.